Proteomic analysis of human breast cancer tissue with laser-capture microdissection and reverse-phase protein microarrays.
Cowherd SM, Espina VA, Petricoin EF 3rd, Liotta LA.
Center for Cancer Research, Laboratory of Pathology, National Cancer Institute, Bethesda, MD 20892, USA.
Despite recent advances in breast cancer therapy, women with similar types of breast cancers may respond very differently to standard treatments. The emerging field of clinical proteomics has the potential to revolutionize breast cancer therapy. The ultimate goal of clinical proteomics is to characterize information flow through protein cascades for individual patients. After the protein networks have been elucidated, drug therapies may be specially designed for each patient. The following review describes the proteomic technologies of laser-capture microdissection (LCM) and reverse-phase protein arrays (RPPAs). These technologies allow scientists to analyze relative abundances of key cellular signaling proteins from pure cell populations. Cell survival and apoptotic protein pathways are currently being monitored with LCM and RPPAs at the National Institutes of Health, in phase II clinical trials of metastatic breast and ovarian cancers. Ultimately, proteomics will become an integral component of tracking and managing individualized breast cancer therapy.
Publication Types:
PMID: 15585078 [PubMed - indexed for MEDLINE]